- Home
- EDUC vs MYNZ Comparison
EDUC vs MYNZ Comparison
Compare EDUC & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- MYNZ
- Stock Information
- Founded
- EDUC 1965
- MYNZ 2021
- Country
- EDUC United States
- MYNZ Germany
- Employees
- EDUC N/A
- MYNZ N/A
- Industry
- EDUC Consumer Specialties
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- EDUC Consumer Discretionary
- MYNZ Health Care
- Exchange
- EDUC Nasdaq
- MYNZ Nasdaq
- Market Cap
- EDUC 16.6M
- MYNZ 15.3M
- IPO Year
- EDUC N/A
- MYNZ 2021
- Fundamental
- Price
- EDUC $1.82
- MYNZ $0.21
- Analyst Decision
- EDUC
- MYNZ Buy
- Analyst Count
- EDUC 0
- MYNZ 2
- Target Price
- EDUC N/A
- MYNZ $3.00
- AVG Volume (30 Days)
- EDUC 6.9K
- MYNZ 5.4M
- Earning Date
- EDUC 01-09-2025
- MYNZ 10-21-2024
- Dividend Yield
- EDUC N/A
- MYNZ N/A
- EPS Growth
- EDUC N/A
- MYNZ N/A
- EPS
- EDUC N/A
- MYNZ N/A
- Revenue
- EDUC $42,415,800.00
- MYNZ $917,203.00
- Revenue This Year
- EDUC N/A
- MYNZ $36.69
- Revenue Next Year
- EDUC N/A
- MYNZ $91.67
- P/E Ratio
- EDUC N/A
- MYNZ N/A
- Revenue Growth
- EDUC N/A
- MYNZ 16.23
- 52 Week Low
- EDUC $0.80
- MYNZ $0.19
- 52 Week High
- EDUC $2.95
- MYNZ $1.79
- Technical
- Relative Strength Index (RSI)
- EDUC 30.95
- MYNZ 40.88
- Support Level
- EDUC $1.87
- MYNZ $0.21
- Resistance Level
- EDUC $2.11
- MYNZ $0.23
- Average True Range (ATR)
- EDUC 0.09
- MYNZ 0.04
- MACD
- EDUC -0.01
- MYNZ -0.00
- Stochastic Oscillator
- EDUC 12.12
- MYNZ 6.88
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.